title: GABAA receptor antagonism ameliorates behavioral and synaptic impairments associated with MeCP2 overexpression.
abstract: Methyl-CpG-binding protein 2 (MeCP2) is a ubiquitously expressed transcriptional regulator with functional importance in the central nervous system. Loss-of-function mutations in MECP2 results in the neurodevelopmental disorder, Rett syndrome, whereas increased expression levels are associated with the neurological disorder, MECP2 duplication syndrome. Previous characterization of a mouse line overexpressing Mecp2 demonstrated that this model recapitulated key behavioral features of MECP2 duplication syndrome with specific deficits in synaptic plasticity and neurotransmission. Alterations in excitation/inhibition balance have been suggested to underlie neurodevelopmental disorders with recent data suggesting that picrotoxin (PTX), a GABAA receptor antagonist, rescues certain behavioral and synaptic phenotypes in a mouse model of Down syndrome. We therefore examined whether a similar treatment regimen would impact the behavioral and synaptic phenotypes in a mouse model of MECP2 duplication syndrome. We report that chronic treatment with low doses of PTX ameliorates specific behavioral phenotypes, including motor coordination, episodic memory impairments, and synaptic plasticity deficits. These findings suggest that GABAA receptor antagonists may offer a possible therapeutic target for the treatment of MECP2 duplication syndrome.
authors.affiliation: Department of Neuroscience, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
authors.forename: Elisa S
authors.initials: ES
authors.lastname: Na
authors.affiliation: Department of Neuroscience, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Morris
authors.affiliation: Department of Neuroscience, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
authors.forename: Erika D
authors.initials: ED
authors.lastname: Nelson
authors.affiliation: Department of Neuroscience, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Monteggia
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D004195:Disease Models, Animal; D058787:GABA-A Receptor Antagonists / Q000627:therapeutic use*; D006624:Hippocampus / Q000187:drug effects; D008297:Male; D038901:X-Linked Intellectual Disability / Q000188:drug therapy*; D051783:Methyl-CpG-Binding Protein 2 / Q000235:genetics; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D009473:Neuronal Plasticity / Q000187:drug effects*; D010852:Picrotoxin / Q000627:therapeutic use*
chemical_list: D058787:GABA-A Receptor Antagonists; D051783:Methyl-CpG-Binding Protein 2; D010852:Picrotoxin; C497393:Mecp2 protein, mouse